Lilly Gets Back Into the Vaccine Business With New Deals
Community Score: 50% | 176 views | 3d
0 community ratings: null thumbs up, null thumbs down
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity drugs to expand into other disease areas. Bloomberg's Gerry Smith reports. -------- More on Bloomberg Television and Markets Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9 Visit http://www.bloomberg.com for business news & analysis, up-to-the-minute market data, features, profiles and more. Connect with Bloomberg Television on: X: https://twitter.com/BloombergTV Facebook: https://www.facebook.com/BloombergTelevision Instagram: https://www.instagram.com/bloombergtv/ Connect with Bloomberg Business on: X: https://twitter.com/business Facebook: https://www.facebook.com/bloombergbusiness Instagram: https://www.instagram.com/bloombergbusiness/ TikTok: https://www.tiktok.com/@b
Tags: Dani Burger, Drug, Drugs, Drugs; Pharmaceuticals, Eli Lilly & Co., Gerry Smith, Medical, Obesity, Science, heart attacks, vaccine
More from Bloomberg Television
- Americans Crave Low-Cost Chinese EVs — Score: 50%
- Bloomberg This Weekend | Shots Fired at WHCD — Score: 50%
- Rep. Beyer: "We Are More Divided Than We've Ever Been" — Score: 50%
- Rep. McCaul on How to Combat Political Violence — Score: 50%
- Sen. Tillis Expected to Clear Way for Kevin Warsh as Fed Chair — Score: 50%
- King Charles' Security Under Review ahead of DC Visit — Score: 50%